Marinus Total Stockholder Equity vs Other Current Liab Analysis

MRNS Stock

USD 9.86 0.14 1.40%

Marinus Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Marinus Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Marinus Pharmaceuticals is a good investment. Please check the relationship between Marinus Pharmaceuticals Total Stockholder Equity and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Total Stockholder Equity vs Other Current Liab

Total Stockholder Equity vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Marinus Pharmaceuticals Total Stockholder Equity account and Other Current Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Marinus Pharmaceuticals' Total Stockholder Equity and Other Current Liab is 0.37. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Marinus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Marinus Pharmaceuticals' Total Stockholder Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Marinus Pharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Stockholder Equity i.e., Marinus Pharmaceuticals' Total Stockholder Equity and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.37

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Other Current Liab

Most indicators from Marinus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Marinus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Marinus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 602.7 M in 2024, whereas Tax Provision is likely to drop slightly above 94 K in 2024.

Marinus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		0.62	0.89	0.83	0.69	0.81	0.55	-0.77	-0.82	0.88	0.99	0.58	0.8	0.4	1.0	0.67	0.78	0.75	0.88	0.74	0.83	-0.59	1.0	0.08	0.67	0.8
Short Long Term Debt Total	0.62		0.78	0.88	-0.08	0.89	0.4	-0.02	-0.88	0.58	0.55	0.25	0.27	0.03	0.61	0.32	0.91	0.85	0.8	0.98	0.9	-0.3	0.63	0.76	0.32	0.89
Other Current Liab	0.89	0.78		0.96	0.37	0.82	0.37	-0.55	-0.81	0.81	0.88	0.5	0.77	0.27	0.89	0.42	0.81	0.73	0.8	0.88	0.88	-0.35	0.88	0.26	0.43	0.82
Total Current Liabilities	0.83	0.88	0.96		0.22	0.88	0.4	-0.39	-0.9	0.79	0.8	0.44	0.68	0.33	0.82	0.42	0.91	0.83	0.86	0.95	0.94	-0.38	0.83	0.4	0.42	0.88
Total Stockholder Equity	0.69	-0.08	0.37	0.22		0.3	0.45	-0.95	-0.3	0.55	0.74	0.52	0.68	0.44	0.69	0.62	0.23	0.29	0.48	0.07	0.28	-0.57	0.67	-0.48	0.62	0.29
Property Plant And Equipment Net	0.81	0.89	0.82	0.88	0.3		0.56	-0.34	-0.97	0.74	0.75	0.47	0.47	0.17	0.79	0.67	0.96	0.9	0.95	0.92	0.99	-0.53	0.8	0.5	0.67	1.0
Current Deferred Revenue	0.55	0.4	0.37	0.4	0.45	0.56		-0.37	-0.56	0.59	0.51	0.38	0.27	0.18	0.53	0.61	0.5	0.56	0.65	0.42	0.53	-0.78	0.54	0.28	0.62	0.56
Net Debt	-0.77	-0.02	-0.55	-0.39	-0.95	-0.34	-0.37		0.35	-0.65	-0.83	-0.49	-0.84	-0.5	-0.78	-0.55	-0.29	-0.31	-0.5	-0.19	-0.36	0.48	-0.76	0.47	-0.55	-0.33
Retained Earnings	-0.82	-0.88	-0.81	-0.9	-0.3	-0.97	-0.56	0.35		-0.73	-0.77	-0.44	-0.51	-0.35	-0.81	-0.62	-0.99	-0.96	-0.97	-0.92	-0.98	0.52	-0.82	-0.5	-0.62	-0.97
Accounts Payable	0.88	0.58	0.81	0.79	0.55	0.74	0.59	-0.65	-0.73		0.87	0.42	0.69	0.22	0.89	0.66	0.67	0.61	0.78	0.69	0.77	-0.67	0.89	0.06	0.66	0.74
Cash	0.99	0.55	0.88	0.8	0.74	0.75	0.51	-0.83	-0.77	0.87		0.54	0.85	0.43	0.99	0.63	0.73	0.71	0.84	0.69	0.78	-0.56	0.99	0.01	0.63	0.75
Non Current Assets Total	0.58	0.25	0.5	0.44	0.52	0.47	0.38	-0.49	-0.44	0.42	0.54		0.58	0.34	0.52	0.44	0.4	0.38	0.52	0.35	0.49	-0.46	0.5	-0.2	0.44	0.47
Non Currrent Assets Other	0.8	0.27	0.77	0.68	0.68	0.47	0.27	-0.84	-0.51	0.69	0.85	0.58		0.67	0.81	0.37	0.48	0.45	0.58	0.45	0.55	-0.34	0.78	-0.33	0.37	0.46
Other Assets	0.4	0.03	0.27	0.33	0.44	0.17	0.18	-0.5	-0.35	0.22	0.43	0.34	0.67		0.4	0.14	0.34	0.41	0.39	0.13	0.24	-0.23	0.38	-0.31	0.14	0.17
Cash And Short Term Investments	1.0	0.61	0.89	0.82	0.69	0.79	0.53	-0.78	-0.81	0.89	0.99	0.52	0.81	0.4		0.65	0.77	0.74	0.86	0.73	0.81	-0.57	1.0	0.08	0.65	0.79
Common Stock Total Equity	0.67	0.32	0.42	0.42	0.62	0.67	0.61	-0.55	-0.62	0.66	0.63	0.44	0.37	0.14	0.65		0.52	0.49	0.69	0.39	0.61	-0.69	0.66	-0.03	1.0	0.66
Common Stock Shares Outstanding	0.78	0.91	0.81	0.91	0.23	0.96	0.5	-0.29	-0.99	0.67	0.73	0.4	0.48	0.34	0.77	0.52		0.97	0.95	0.94	0.97	-0.45	0.78	0.55	0.52	0.96
Other Current Assets	0.75	0.85	0.73	0.83	0.29	0.9	0.56	-0.31	-0.96	0.61	0.71	0.38	0.45	0.41	0.74	0.49	0.97		0.93	0.87	0.9	-0.43	0.76	0.55	0.49	0.9
Other Stockholder Equity	0.88	0.8	0.8	0.86	0.48	0.95	0.65	-0.5	-0.97	0.78	0.84	0.52	0.58	0.39	0.86	0.69	0.95	0.93		0.85	0.95	-0.66	0.87	0.37	0.7	0.95
Total Liab	0.74	0.98	0.88	0.95	0.07	0.92	0.42	-0.19	-0.92	0.69	0.69	0.35	0.45	0.13	0.73	0.39	0.94	0.87	0.85		0.95	-0.36	0.74	0.63	0.39	0.92
Property Plant And Equipment Gross	0.83	0.9	0.88	0.94	0.28	0.99	0.53	-0.36	-0.98	0.77	0.78	0.49	0.55	0.24	0.81	0.61	0.97	0.9	0.95	0.95		-0.5	0.83	0.48	0.62	0.99
Preferred Stock Total Equity	-0.59	-0.3	-0.35	-0.38	-0.57	-0.53	-0.78	0.48	0.52	-0.67	-0.56	-0.46	-0.34	-0.23	-0.57	-0.69	-0.45	-0.43	-0.66	-0.36	-0.5		-0.57	-0.03	-0.69	-0.53
Total Current Assets	1.0	0.63	0.88	0.83	0.67	0.8	0.54	-0.76	-0.82	0.89	0.99	0.5	0.78	0.38	1.0	0.66	0.78	0.76	0.87	0.74	0.83	-0.57		0.11	0.66	0.8
Short Term Debt	0.08	0.76	0.26	0.4	-0.48	0.5	0.28	0.47	-0.5	0.06	0.01	-0.2	-0.33	-0.31	0.08	-0.03	0.55	0.55	0.37	0.63	0.48	-0.03	0.11		-0.03	0.51
Common Stock	0.67	0.32	0.43	0.42	0.62	0.67	0.62	-0.55	-0.62	0.66	0.63	0.44	0.37	0.14	0.65	1.0	0.52	0.49	0.7	0.39	0.62	-0.69	0.66	-0.03		0.67
Property Plant Equipment	0.8	0.89	0.82	0.88	0.29	1.0	0.56	-0.33	-0.97	0.74	0.75	0.47	0.46	0.17	0.79	0.66	0.96	0.9	0.95	0.92	0.99	-0.53	0.8	0.51	0.67

Click cells to compare fundamentals

Marinus Pharmaceuticals Account Relationship Matchups

Marinus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Liab	4.8M	8.0M	21.2M	46.9M	22.1M	23.2M
Total Current Liabilities	8.0M	10.7M	40.6M	54.9M	40.6M	42.7M
Total Stockholder Equity	87.8M	137.2M	53.5M	116M	16.8M	15.9M
Property Plant And Equipment Net	2.3M	1.9M	2.5M	4.2M	4.8M	5.1M
Net Debt	(90.5M)	(138.0M)	(82.1M)	(167.9M)	(10.2M)	(10.7M)
Retained Earnings	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(571.9M)	(543.3M)
Accounts Payable	2.8M	2.2M	3.1M	6.3M	4.0M	2.6M
Cash	90.9M	138.5M	122.9M	240.6M	120.6M	88.1M
Non Current Assets Total	4.7M	10.3M	13.9M	19.0M	5.7M	7.8M
Non Currrent Assets Other	2.4M	6.9M	11.4M	14.7M	819.0K	778.0K
Cash And Short Term Investments	91.7M	138.5M	122.9M	240.6M	150.3M	92.1M
Common Stock Total Equity	53K	87K	37K	50K	57.5K	35.9K
Common Stock Shares Outstanding	13.6M	27.3M	36.7M	39.1M	53.7M	56.4M
Liabilities And Stockholders Equity	98.8M	150.5M	136.8M	259.5M	170.9M	102.1M
Other Current Assets	2.5M	6.3M	6.1M	5.4M	8.7M	9.2M
Other Stockholder Equity	295.1M	444.6M	459.9M	542.4M	588.7M	618.1M
Total Liab	11.1M	13.3M	83.4M	143.5M	154.1M	161.9M
Property Plant And Equipment Gross	2.3M	1.9M	3.9M	5.7M	5.7M	6.0M
Total Current Assets	94.1M	140.2M	122.9M	240.6M	165.2M	94.3M
Accumulated Other Comprehensive Income	(96K)	(2K)	0.0	(20K)	(23K)	(24.2K)
Common Stock	53K	87K	37K	50K	55K	37.9K
Property Plant Equipment	2.3M	1.9M	2.5M	4.2M	4.9M	5.1M
Net Tangible Assets	87.8M	132.7M	53.5M	112.0M	128.8M	76.0M
Retained Earnings Total Equity	(235.6M)	(311.9M)	(410.7M)	(430.5M)	(387.5M)	(368.1M)
Short Term Investments	19.9M	5.0M	739K	1.5M	29.7M	31.2M
Non Current Liabilities Total	3.0M	2.5M	42.8M	88.6M	113.5M	119.2M
Capital Surpluse	295.1M	444.6M	459.9M	542.4M	623.8M	317.7M
Net Invested Capital	59.6M	132.7M	40.8M	71.0M	89.7M	81.7M

Pair Trading with Marinus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marinus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marinus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Marinus Stock

0.64

VCEL

Vericel Corp Ord

Pair Corr

Moving against Marinus Stock

0.57	ELDN	Eledon Pharmaceuticals Earnings Call This Week	Pair Corr
0.55	EDIT	Editas Medicine	Pair Corr
0.51	VTVT	vTv Therapeutics	Pair Corr
0.47	ENTA	Enanta Pharmaceuticals Fiscal Year End 18th of November 2024	Pair Corr
0.43	ENSC	Ensysce Biosciences	Pair Corr

The ability to find closely correlated positions to Marinus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marinus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marinus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marinus Pharmaceuticals to buy it.

The correlation of Marinus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marinus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marinus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Marinus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Marinus Stock Analysis

When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC